T1	Participants 918 1046	A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 μm or smaller, were studied.
T2	Participants 1047 1115	Analysis was by intent-to-treat population and performed in May 2013
T3	Participants 1131 1359	Patients with symptomatic VMA/VMT were randomly assigned (2:1 or 3:1 in study TG-MV-006 and study TG-MV-007, respectively) to receive a single intravitreal injection of ocriplasmin, 125 μg, or placebo-injected vehicle (placebo).
